Long-Term Effect of TEV-48574 in Ulcerative Colitis or Crohn's Disease

Study Title
A Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Treatment Phase of the Dose-Ranging Study (RELIEVE UCCD LTE)
Teva Identifier
TV48574-IMM-20038
ClinicalTrials.gov Identifier
NCT05668013
Study Status
Active, not recruiting
Trial Condition(s)
Crohn's DiseaseColitis, Ulcerative
Interventions
Drug: TEV-48574
EudraCT Number
2022-002593-89
EU CT Number
2024-515027-11-00

Study Description

Primary objectives:
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD).

Secondary objective:
- Evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD
- Evaluate the safety and tolerability of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD
- Evaluate the immunogenicity of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD The total duration for a participant in the double-blind period only is 66 weeks; and for a participant in the open-label extension (OLE) period, up to an additional 268 weeks.

Print

Participation criteria and map of study locations

EudraCT

CTIS


Key Participation Requirements

Gender
Female, Male
Age Range
Adult
Phase
Phase 3

Study Type

Interventional